Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly secured close to RMB 100 million (USD 14.96 million) in a Series A financing round co-led by Oriza Seed and Apricot Capital. The proceeds will be directed toward advancing technology platforms in proteomics and spatialomics, as well as developing and obtaining regulatory approval for its next-generation ultrasensitive single-molecule protein detection system and associated neurodegenerative disease marker detection kits.
Company Background
Founded in 2019, Iomics Biosciences focuses on the brain science and tumor sectors. The company is recognized for its cutting-edge technology platforms, including ultrasensitive protein detection, high-throughput transcriptome, and spatial proteome capabilities.
Future Development
With the fresh capital, Iomics Biosciences aims to enhance its technological edge in the proteomics and spatialomics fields. The development of its next-generation ultrasensitive single-molecule protein detection system is a key priority, alongside the creation of detection kits for neurodegenerative disease markers. These advancements are expected to bolster the company’s position in the diagnostic equipment market and support its growth in research and commercial applications.-Fineline Info & Tech
